ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

CEPI

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa	University of Oxford	IAVI, Emergent			
MERS		IDT, Barinthus/ University of Oxford			
Nipah		PHV, University of Oxford, Auro Vaccines			
Rift Valley fever (RVF)	UC Davis	Wageningen U.			
Chikungunya				IVI/Bharat	Valneva
COVID-19 (*)		Gritstone			SK Bioscience, Biological E, Moderna, Clover, Novavax, AZ/Oxford, University of Hong Kong
Broadly protective Betacoronavirus (BPBC)	MigVax, VIDO, Bionet, CPI/CalTech, Bharat/U Syd/ExcellGene, NEC, SK Bioscience, Intravacc, Panacea/ THSTI, Gritstone	VBI			

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

CEPI

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Disease X	Akagera Chungbuk University University of Queensland Moderna SK bio University of Oxford Tiba bio Gennova Celestial Emervax HMRI	BioNTech Lemonex			

DISEASE	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING	
 Lassa	University of Oxford	Preclinical	Viral Vector	up to US $19.0 million	(‡)
	IAVI	Phase I	Viral Vector	up to US $64.4 million	
	Emergent + PATH	Phase I	Viral vector	up to US $36.0 million	
MERS	University of Oxford + Barinthus	Phase I	Viral vector	up to US $34.8 million	(‡)
	IDT	Phase I	Viral vector	up to US $36.0 million	
 Nipah	University of Oxford	Phase I	Viral Vector	up to US $19.0 million	(‡)
	Auro Vaccines + PATH	Phase I	Protein based	up to US $25.0 million	
	PHV	Phase I	Viral vector	up to US $43.6 million	
 Rift Valley fever (RVF)	UC Davis	Preclinical	Live attenuated	up to US $40 million	
	Wageningen University	Phase I	Live attenuated	up to US $38.4 million	
 Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated	up to US $14.1 million	
	Valneva	Registration	Live attenuated	up to US $24.6 million	
 COVID-19	Gritstone	Phase I	RNA	up to US $25.6 million	(**)
	SK Bioscience	Registration	Protein based	up to US $210.0 million	
	Biological E	Registration	Protein based	up to US $14.0 million	
	Moderna	Registration	Protein based	up to US $1.0 million	
	Clover	Registration	Protein based	up to US $397.4 million	
	AZ/University of Oxford	Registration	Viral vector	up to US $384.0 million	
	Novavax	Registration	Protein based	up to US $399.0 million	

(‡) Includes Lassa, MERS and Nipah funding

(**) Includes COVID-19 variant and BPBC funding

RVF, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

PATHOGEN	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING
 Broadly protective Beta-coronavirus (BPBC)	MigVax	Preclinical	Protein based	up to US $4.3 million
	BioNet	Preclinical	RNA	up to US $16.9 million
	VIDO	Preclinical	Protein based	up to US $5.0 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	up to US $19.9 million
	CPI/Caltech	Preclinical	Protein based	up to US $30.0 million
	NEC	Preclinical	RNA	up to US $4.8 million
	SK Bioscience	Preclinical	Protein based	up to US $50.0 million
	Panacea/THSTI	Preclinical	Protein based	up to US $12.5 million
	Intravacc	Preclinical	Protein based	up to US $4.8 million
	Gritstone	Phase I	RNA	Up to US $25.6 million (**)
Disease X 	Akagera	Preclinical	RNA	up to US $1.5 million
	BioNTech	Phase I	RNA	up to US $90.0 million
	Celestial	Preclinical	RNA	up to US $0.7 million
	Chungbuk National University	Preclinical	RNA	up to US $0.9 million
	Emervax	Preclinical	RNA	up to US $2.2 million
	Gennova	Preclinical	RNA	up to US $3.6 million
	HMRI	Preclinical	RNA	Up to US $3.8 million
	Lemonex	Phase I	RNA	up to US $4.9 million
	Moderna	Preclinical	RNA	The strategic partnership is not yet at a stage where CEPI provides funding to Moderna.
	University of Oxford	Preclinical	Viral Vector	up to US $80.0 million
	University of Queensland	Preclinical	Protein based	up to US $10.6 million
	SK Bioscience	Preclinical	RNA	up to US $40.0 million
	Tiba bio	Preclinical	RNA	up to US $2.0 million